PMID- 31172196
OWN - NLM
STAT- MEDLINE
DCOM- 20200325
LR  - 20200325
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 152
IP  - 4
DP  - 2019 Sep 9
TI  - American Society of Clinical Oncology/College of American Pathologists 2018 
      Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a 
      National Reference Laboratory.
PG  - 479-485
LID - 10.1093/ajcp/aqz061 [doi]
AB  - OBJECTIVES: To review impact of the ASCO/CAP 2018 update on HER2 testing. 
      METHODS: HER2 fluorescence in situ hybridization (FISH) test requests from 
      primary and metastatic breast cancers between August 2018 and January 2019 were 
      included. FISH results requiring a changed algorithm under the new guidelines 
      (groups 2, 3, and 4) were identified and HER2:CEN17 ratios, average HER2, CEN17 
      signals/cell, and HER2 immunohistochemistry (IHC) results were recorded. RESULTS: 
      Of the HER2 FISH cases 176/812(21.7%) fell within groups 2, 3, or 4; 0/12, 1/12, 
      and 2/152 cases were positive (3+) by IHC, and 1/12, 2/12, and 6/152 cases were 
      positive after targeted scoring from groups 2, 3, and 4, respectively. Following 
      2018 updates, 8.3%, 25%, and 5.3% of the groups 2, 3, and 4 were positive, 
      respectively. CONCLUSIONS: Groups 2, 3, and 4 constituted over 20% of HER2 FISH 
      tests in a reference laboratory. The 2018 ASCO/CAP update significantly decreased 
      the HER2 positivity rate.
CI  - (c) American Society for Clinical Pathology, 2019. All rights reserved. For 
      permissions, please e-mail: journals.permissions@oup.com.
FAU - Lin, Leo
AU  - Lin L
AD  - Department of Pathology, University of Utah, Salt Lake City.
FAU - Sirohi, Deepika
AU  - Sirohi D
AD  - Department of Pathology, University of Utah, Salt Lake City.
FAU - Coleman, Joshua F
AU  - Coleman JF
AD  - Department of Pathology, University of Utah, Salt Lake City.
FAU - Gulbahce, H Evin
AU  - Gulbahce HE
AD  - Department of Pathology, University of Utah, Salt Lake City.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Breast Neoplasms/genetics/*metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Practice Guidelines as Topic
MH  - Receptor, ErbB-2/genetics/*metabolism
OTO - NOTNLM
OT  - Breast cancer
OT  - FISH
OT  - HER2
EDAT- 2019/06/07 06:00
MHDA- 2020/03/26 06:00
CRDT- 2019/06/08 06:00
PHST- 2019/06/07 06:00 [pubmed]
PHST- 2020/03/26 06:00 [medline]
PHST- 2019/06/08 06:00 [entrez]
AID - 5512208 [pii]
AID - 10.1093/ajcp/aqz061 [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2019 Sep 9;152(4):479-485. doi: 10.1093/ajcp/aqz061.